Skip to main content

Table 3 Risk factors for overall survival, time to progress, and hepatic metastasis-free survival in the anti-HBc positive CRC patients undergoing curative surgical resection

From: Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer

Variable Overall survival Time to progress Hepatic metastasis-free survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value
Anti-HBc
  ≥ 8.8 3.18 1.564–6.463 < 0.001* 3.51 1.718–7.17 < 0.001* 4.889 2.397–9.97 < 0.001* 5.747 2.789–11.842 < 0.001* 3.754 1.054–13.369 0.04* 3.754 1.054–13.369 0.04*
 < 8.8 Reference                 
FIB-4                   
  ≥ 1.45 1.48 0.718–3.05 0.288     1.018 0.484–2.139 0.963     0.983 0.254–3.806 0.981    
 < 1.45 Reference                 
NLR                   
  ≥ 3.4 1.418 0.634–3.171 0.395     1.41 0.635–3.129 0.398     1.753 0.453–6.783 0.416    
 < 3.4 Reference                 
Anti-HBs
 Positive 1.093 0.515–2.321 0.817     0.873 0.429–1.774 0.706     0.756 0.213–2.68 0.665    
 Negative Reference                 
HBsAg
 Positive 2.296 0.802–6.572 0.121     2.154 0.755–6.141 0.151     3.877 0.821–18.311 0.087    
 Negative Reference                 
Retrieved LN
  ≥ 12 0.983 0.453–2.135 0.966     0.94 0.447–1.975 0.869     1.66 0.352–7.82 0.521    
 < 12 Reference                 
Neoadjuvant therapy
 Yes 0.735 0.175–3.083 0.674     1.544 0.542–4.395 0.416     0.043 0–729.474 0.527    
 No Reference                 
CEA (ng/ml)                  
 > 5 1.286 0.636–2.602 0.484     0.911 0.453–1.831 0.793     3.352 0.867–12.965 0.08    
  ≤ 5 Reference                 
CA19-9(U/ml)                   
 > 37 1.683 0.725–3.907 0.226     1.282 0.529–3.106 0.582     0.634 0.08–5.008 0.666    
  ≤ 37 Reference                 
TNM stage                   
 III 2.731 1.285–5.802 0.01* 3.038 1.423–6.484 <0.001* 3.038 1.444–6.39 <0.001* 3.722 1.752–7.908 <0.001* 1.921 0.541–6.822 0.312    
 II Reference                 
Gender                   
 Male 1.211 0.542–2.709 0.64     0.853 0.414–1.759 0.667     0.966 0.25–3.737 0.96    
 Female Reference                 
Age (years)                   
  ≥ 61 1.124 0.554–2.28 0.747     0.922 0.466–1.825 0.816     0.896 0.259–3.094 0.862    
 < 61 Reference                 
  1. Abbreviations: anti-HBc antibodies to hepatitis B core antigen, anti-HBs antibodies to hepatitis B surface antigen, HBsAg hepatitis B surface antigen, NLR neutrophil to lymphocyte ratio, CA19-9 cancer antigen 19-9, CEA carcinoembryonic antigen, ALT alanine transaminase, AST aspartate transaminase, ALP alkaline phosphatase, PLT platelets
  2. *Significant at P < 0.05
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us